Table 1. Clinical characteristics and... | American Society of Hematology

Table 1.

Clinical characteristics and patient follow-up

Patient no.	Age/sex	Past history	Past treatment	Extramedullary sites of involvement				Initial therapy^5-152	CR/PR	Outcome Relapse	Survival
Patient no.	Age/sex	Past history	Past treatment	Skin	Lymph node	Spleen	Other	Initial therapy^5-152	CR/PR	Outcome Relapse	Survival
1^5-150	76/M	RA	Symptomatic		+	+	+	Symptomatic	No		3 mo+
2	8/M	None	None	+	+	+	+	Cytarabine, mitoxantrone	CR	Yes, at mo 12	37 mo+
3	86/F	None	None	+				Symptomatic	No		3 mo+
4	81/F	None	None	+	+			Cyclophosphamide, vincristine, prednisone	CR	Yes, at mo 6	12 mo+
5	68/F	None	None	+				Lomustine, adriamycin, cytarabine	CR	Yes, at mo 18	22 mo
6	69/M	None	None	+	+		+	Cyclophosphamide, vincristine, prednisone	CR	Yes, at mo 12	12 mo+
7	75/M	None	None		+	+		VP16/AraC/ifosfamide	CR	Yes, at mo 4	6 mo+
8	72/M	None	None	+	+			Cyclophosphamide, epirubicine, vincristine, prednisone	PR	Yes, at mo 9	23 mo+
9	6/F	None	None		+	+		Rubidomycine, prednisone, asparaginase, vincristine + allogenic BMT at the first CR	CR	No	98 mo
10	55/M	One son dead of AML3	None	+				Lomustine, adriamycin, cytarabine	CR	Yes, at mo 15	16 mo+
11^5-151	79/M	None	None	+				Cyclophosphamide, VP16, prednisone	CR	Yes, at mo 6	8 mo+
12	14/M	None	None	+				Vincristine, prednisone, daunorubicin, asparaginase^5-151	CR	No	10 mo
13^5-151	74/M	None	None	+				VP16/ifosfamide	CR	Yes, at mo 6	17 mo+
14	74/F	One sister with breast carcinoma	None	+				Vincristine, 6-mercaptopurine, cyclophosphamide, cytarabine	CR	No	5 mo
15^5-150	67/M	RAEB + cutaneous nodule	Electron-therapy + caryolysine + hydroxyurea	+		+	+	Idarubicine, cytarabine	CR	Yes, at mo 3	5 mo
16	75/F	None	None	+	+	+	+	Prednisone, vincristine, cyclophosphamide, daunorubicin	No		9 mo+
17	60/M	None	None	+	+			Lomustine, adriamycin, cytarabine	CR	Yes, at mo 8	9 mo+
18	82/M	None	None	+				Vincristine, cyclophosphamide, adriamycin	CR		4 mo
19	56/M	Cutaneous nodules one month before	None	+	+			Daunorubicin, cytarabine	CR	Yes, at mo 9	13 mo+
20	67/M	None	None	+	+	+		6-Mercaptopurine, methotrexate, prednisone	PR	Yes, at mo 5	12 mo
21	70/M	None		+	+	+	+	Cyclophosphamide, vincristine, prednisone	CR	Yes, at mo 6	7 mo+
22^5-151	28/M	None	None	+				Cyclophosphamide, adriamycin, vincristine, prednisone, allogenic BMT at the first CR	CR	Yes, at mo 12	38 mo+
23	29/M	None	None			+		Cyclophosphamide, adriamycin, vincristine, prednisone, allogenic BMT at the first CR	CR	No	76 mo

Frequencies	17/M (74%), 6/F (26%)			19/23 (83%)	12/23 (52%)	9/23 (39%)	6/23 (26%)		18 CR (78%)	15 relapses/ 18 (83%),	Median = 12 mo
									2 PR (9%)	Median, 9 mo	(range 3-96 mo)
				14/23 (61%) with both

Patient no.	Age/sex	Past history	Past treatment	Extramedullary sites of involvement				Initial therapy^5-152	CR/PR	Outcome Relapse	Survival
Patient no.	Age/sex	Past history	Past treatment	Skin	Lymph node	Spleen	Other	Initial therapy^5-152	CR/PR	Outcome Relapse	Survival
1^5-150	76/M	RA	Symptomatic		+	+	+	Symptomatic	No		3 mo+
2	8/M	None	None	+	+	+	+	Cytarabine, mitoxantrone	CR	Yes, at mo 12	37 mo+
3	86/F	None	None	+				Symptomatic	No		3 mo+
4	81/F	None	None	+	+			Cyclophosphamide, vincristine, prednisone	CR	Yes, at mo 6	12 mo+
5	68/F	None	None	+				Lomustine, adriamycin, cytarabine	CR	Yes, at mo 18	22 mo
6	69/M	None	None	+	+		+	Cyclophosphamide, vincristine, prednisone	CR	Yes, at mo 12	12 mo+
7	75/M	None	None		+	+		VP16/AraC/ifosfamide	CR	Yes, at mo 4	6 mo+
8	72/M	None	None	+	+			Cyclophosphamide, epirubicine, vincristine, prednisone	PR	Yes, at mo 9	23 mo+
9	6/F	None	None		+	+		Rubidomycine, prednisone, asparaginase, vincristine + allogenic BMT at the first CR	CR	No	98 mo
10	55/M	One son dead of AML3	None	+				Lomustine, adriamycin, cytarabine	CR	Yes, at mo 15	16 mo+
11^5-151	79/M	None	None	+				Cyclophosphamide, VP16, prednisone	CR	Yes, at mo 6	8 mo+
12	14/M	None	None	+				Vincristine, prednisone, daunorubicin, asparaginase^5-151	CR	No	10 mo
13^5-151	74/M	None	None	+				VP16/ifosfamide	CR	Yes, at mo 6	17 mo+
14	74/F	One sister with breast carcinoma	None	+				Vincristine, 6-mercaptopurine, cyclophosphamide, cytarabine	CR	No	5 mo
15^5-150	67/M	RAEB + cutaneous nodule	Electron-therapy + caryolysine + hydroxyurea	+		+	+	Idarubicine, cytarabine	CR	Yes, at mo 3	5 mo
16	75/F	None	None	+	+	+	+	Prednisone, vincristine, cyclophosphamide, daunorubicin	No		9 mo+
17	60/M	None	None	+	+			Lomustine, adriamycin, cytarabine	CR	Yes, at mo 8	9 mo+
18	82/M	None	None	+				Vincristine, cyclophosphamide, adriamycin	CR		4 mo
19	56/M	Cutaneous nodules one month before	None	+	+			Daunorubicin, cytarabine	CR	Yes, at mo 9	13 mo+
20	67/M	None	None	+	+	+		6-Mercaptopurine, methotrexate, prednisone	PR	Yes, at mo 5	12 mo
21	70/M	None		+	+	+	+	Cyclophosphamide, vincristine, prednisone	CR	Yes, at mo 6	7 mo+
22^5-151	28/M	None	None	+				Cyclophosphamide, adriamycin, vincristine, prednisone, allogenic BMT at the first CR	CR	Yes, at mo 12	38 mo+
23	29/M	None	None			+		Cyclophosphamide, adriamycin, vincristine, prednisone, allogenic BMT at the first CR	CR	No	76 mo

Frequencies	17/M (74%), 6/F (26%)			19/23 (83%)	12/23 (52%)	9/23 (39%)	6/23 (26%)		18 CR (78%)	15 relapses/ 18 (83%),	Median = 12 mo
									2 PR (9%)	Median, 9 mo	(range 3-96 mo)
				14/23 (61%) with both

“Other” was liver for patients 1, 2, 15, 16, and 21; tonsils for patients 6 and 21; lung, eyes, and CNS for patient 6. lomustine, indicates lomustine; BMT, bone marrow transplantation; CR, complete remission; PR, partial remission; No, absence of remission; +, death. In case of relapse, the date of the first relapse is indicated. Patient 9 was treated according to EORTC58881 VHR protocol, patient 12 according to the FRALLE 2000-BT protocol, and patient 15 according to the GOELAL protocol for adults.

F5-150

Diagnosis of refractory anemia without excess of blasts (RA) 3 years previously for patient 1; diagnosis of RAEB 2 years previously for patient 15.

F5-151

Initial cutaneous localization and secondary medullary dissemination.

F5-152

Generic names are followed by their proprietary products: cytarabine, Aracytine; cyclophosphamide, Endoxan; ifosfamide, Holoxan; mitoxantrone, Novantrone; vincristine, Oncovin; 6-mercaptopurine, Purinethol.

View Large

This Feature Is Available To Subscribers Only